Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.

Maria Domenica CappelliniAli T TaherAntonio PigaFarrukh ShahErsi VoskaridouVip ViprakasitJohn B PorterOlivier HermineEllis J NeufeldAlexis A ThompsonDerek TangAylin YucelJennifer Lord-BessenPeiwen YuShien GuoJeevan K ShettyDimana MitevaTatiana ZingerJay T BackstromEsther Natalie Oliva

Published in: European journal of haematology (2023)

Luspatercept + BSC reduced transfusion burden while maintaining patients' HRQoL. HRQoL domain improvements from baseline through 48 weeks were also enhanced for luspatercept responders.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
sickle cell disease
clinical trial
peritoneal dialysis
cardiac surgery
phase iii
machine learning
phase ii
artificial intelligence